الفهرس 
Anatomy of the liverOnly 14 pages are availabe for public view
 |  | from | 192 |  |  |
| | | from | 192 | | |
Abstract
Background: Hepatocellular carcinoma (HCC) is the third cause of cancer death and the leading cause of mortality among cirrhotic patients
Aim: The aim of this study is to assess and compare the diagnostic and prognostic value of serum transforming growth factor α (TGF-α) and serum arginase versus alpha fetoprotein in Egyptian HCC patients before and after local ablative therapy.
Methods: This study was conducted on 40 patients with HCC (cases) and 10 other patients with liver cirrhosis only (controls) during the period from February 2015 till may 2016, Cases underwent loco regional treatment with Radio frequency ablation (RFA) or Trans arterial chemo embolization (TACE). Results of the different tumour markers were collected and statistically analyzed by appropriate statistical methods.
Results: Control patients were investigated for different tumour markers (alpha fetoprotein, serum TGF-α and serum arginase) and results compared with the levels of these tumour markers in HCC cases. HCC patients were investigated for the level of (alpha fetoprotein, serum TGF-α and serum arginase) before intervention and one month after intervention as well. The results showed that, there is a highly statistically significant difference between cases and controls as regard base line alpha fetoprotein, serum TGF-α and serum arginase (P<0.01). The cut off value of alpha fetoprotein was (45ng/dl) and showed 82.5% Sensitivity and 100% Specificity. While the cutoff point of serum TGF-α was (205 pg/ml), with 100% Sensitivity and 90% Specificity, and the cutoff point of serum Arginase was (20.5 ng/ml), with 95% Sensitivity and 100% Specificity. The mean alpha fetoprotein, serum TGF-α and serum arginase levels showed significant decrease after RFA in and TACE (P<0.01).
Conclusion: Serum TGF-α and serum arginase can be considered as diagnostic tools for development of HCC in patient with liver cirrhosis better than alpha fetoprotein. And can be used for follow up after locoregional treatment of HCC with RFA or TACE.